Next-generation sequencing (NGS) of tumor tissue specimens from cervical LN identified ROS1 fusion, along with TP53, RB1, PTEN, and TERT mutations; microsatellite stability; tumor mutational burden (TMB) of 34.9 mutations/Mb; PD-L1 (Tumor proportion score: 0%) (As shown in Table 1; Figure 2). The gene discussed is ROS1; the disease is neoplasm.